総資産利益率 (ROA)
2012年以降
計算
AbbVie Inc.、 ROA、長期トレンド計算
| ROA | = | 100 | × | アッヴィに帰属する当期純利益1 | ÷ | 総資産1 | |
|---|---|---|---|---|---|---|---|
| 2024/12/31 | 3.17% | = | 100 | × | 4,278) | ÷ | 135,161) |
| 2023/12/31 | 3.61% | = | 100 | × | 4,863) | ÷ | 134,711) |
| 2022/12/31 | 8.53% | = | 100 | × | 11,836) | ÷ | 138,805) |
| 2021/12/31 | 7.88% | = | 100 | × | 11,542) | ÷ | 146,529) |
| 2020/12/31 | 3.07% | = | 100 | × | 4,616) | ÷ | 150,565) |
| 2019/12/31 | 8.84% | = | 100 | × | 7,882) | ÷ | 89,115) |
| 2018/12/31 | 9.58% | = | 100 | × | 5,687) | ÷ | 59,352) |
| 2017/12/31 | 7.50% | = | 100 | × | 5,309) | ÷ | 70,786) |
| 2016/12/31 | 9.01% | = | 100 | × | 5,953) | ÷ | 66,099) |
| 2015/12/31 | 9.70% | = | 100 | × | 5,144) | ÷ | 53,050) |
| 2014/12/31 | 6.44% | = | 100 | × | 1,774) | ÷ | 27,547) |
| 2013/12/31 | 14.14% | = | 100 | × | 4,128) | ÷ | 29,198) |
| 2012/12/31 | 19.53% | = | 100 | × | 5,275) | ÷ | 27,008) |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).
1 百万米ドル
競合他社との比較
AbbVie Inc.、 ROA、長期トレンド、競合他社との比較
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024/12/31 | 3.17% | 4.45% | -9.66% | 5.03% | 13.45% | 0.81% | 7.81% | 14.62% | 3.76% | 11.69% | 6.51% | -2.38% |
| 2023/12/31 | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% | 15.92% |
| 2022/12/31 | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% | 18.30% |
| 2021/12/31 | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% | 17.44% |
| 2020/12/31 | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% | 23.07% |
| 2019/12/31 | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% | 14.15% |
| 2018/12/31 | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% | 33.57% |
| 2017/12/31 | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% | 7.43% |
| 2016/12/31 | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% | -3.87% |
| 2015/12/31 | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% | -22.26% |
| 2014/12/31 | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% | -31.63% |
| 2013/12/31 | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% | -19.19% |
| 2012/12/31 | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% | -3.88% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).
産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
AbbVie Inc.、 ROA、長期トレンド、産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
| AbbVie Inc. | 製薬、バイオテクノロジー、ライフサイエンス | |
|---|---|---|
| 2024/12/31 | 3.17% | 5.30% |
| 2023/12/31 | 3.61% | 7.25% |
| 2022/12/31 | 8.53% | 10.67% |
| 2021/12/31 | 7.88% | 10.42% |
| 2020/12/31 | 3.07% | 5.45% |
| 2019/12/31 | 8.84% | 9.02% |
| 2018/12/31 | 9.58% | 8.97% |
| 2017/12/31 | 7.50% | 5.28% |
| 2016/12/31 | 9.01% | 8.61% |
| 2015/12/31 | 9.70% | 8.93% |
| 2014/12/31 | 6.44% | 9.45% |
| 2013/12/31 | 14.14% | 9.46% |
| 2012/12/31 | 19.53% | 8.30% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).
業界との比較: 医療
AbbVie Inc.、 ROA、長期トレンド、業界との比較: 医療
| AbbVie Inc. | 医療 | |
|---|---|---|
| 2024/12/31 | 3.17% | 5.25% |
| 2023/12/31 | 3.61% | 6.71% |
| 2022/12/31 | 8.53% | 8.71% |
| 2021/12/31 | 7.88% | 8.70% |
| 2020/12/31 | 3.07% | 5.45% |
| 2019/12/31 | 8.84% | 7.57% |
| 2018/12/31 | 9.58% | 6.72% |
| 2017/12/31 | 7.50% | 5.31% |
| 2016/12/31 | 9.01% | 7.18% |
| 2015/12/31 | 9.70% | 7.54% |
| 2014/12/31 | 6.44% | 8.41% |
| 2013/12/31 | 14.14% | 8.58% |
| 2012/12/31 | 19.53% | 7.94% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31).